Search results for "Compromise"

showing 10 items of 220 documents

Oral appliance therapy in obstructive sleep apnea: Long-term adherence and patients experiences.

2018

Background Despite the advances in the treatment of obstructive sleep apnea (OSA) with mandibular advancement appliances (MAA), their effectiveness is dependent on the patients’ compliance. Our aims were to evaluate the long-term adherence to MAA therapy and patients’ experiences of the treatment in OSA. Material and Methods Sixty-nine patients (52 males, 17 females; Mean age: 54.4±10.8 years) were included in the study. The subjects were mild (56%) and moderate (44%) OSA patients who had been treated using MAA at least 4 years prior to the study. A phone survey was used to determine the demographic characteristics of the patients, as well as to assess self-reported adherence to therapy, su…

AdultMalemedicine.medical_specialtyTime FactorsOral applianceDisease03 medical and health sciences0302 clinical medicinePatient satisfactionInternal medicinemedicineHumansGeneral DentistryIncome.statusAgedSleep Apnea Obstructivebusiness.industryResearchSleep apneaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in DentistryTemporomandibular jointObstructive sleep apneamedicine.anatomical_structure030228 respiratory systemOtorhinolaryngologyPatient SatisfactionUNESCO::CIENCIAS MÉDICASMarital statusPatient ComplianceSurgeryFemalebusinessMandibular Advancement030217 neurology & neurosurgeryMedicina oral, patologia oral y cirugia bucal
researchProduct

Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients

2020

Abstract Diagnosis, treatment, and management of invasive mould infections (IMI) are challenged by several risk factors, including local epidemiological characteristics, the emergence of fungal resistance and the innate resistance of emerging pathogens, the use of new immunosuppressants, as well as off-target effects of new oncological drugs. The presence of specific host genetic variants and the patient's immune system status may also influence the establishment of an IMI and the outcome of its therapy. Immunological components can thus be expected to play a pivotal role not only in the risk assessment and diagnosis, but also in the treatment of IMI. Cytokines could improve the reliability…

AdultMalemedicine.medical_specialtyTreatment responseAntifungal Agentshemato-oncological malignanciesAspergillosismucormycosis03 medical and health sciencesImmunocompromised HostImmune systemSDG 3 - Good Health and Well-beingInternal medicineNeoplasmsEpidemiologyimmunological statusmedicineHumansIntensive care medicine030304 developmental biologyAgedAged 80 and over0303 health sciencesHematology030306 microbiologybusiness.industryinvasive pulmonary aspergillosishematologyMucormycosisCancerReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseInfectious Diseaseshemato-oncological malignancies; hematology; immunological status; invasive pulmonary aspergillosis; mucormycosisAcademicSubjects/SCI00960FemaleOriginal ArticleRisk assessmentbusinessAcademicSubjects/MED00010Invasive Fungal Infections
researchProduct

State anxiety and depression as factors modulating and influencing postoperative pain in dental implant surgery. A prospective clinical survey

2013

Objetives: To determine whether preoperative state anxiety and depression modulate or influence objective and subjective postoperative pain following dental implant insertion. Study Design: Prospective, clinical study with 7-day follow-up of a sample of 105 subjects who preoperatively completed the state anxiety questionnaire (STAI-E) and Beck Depression Inventory (BDI) and postoperatively, at 2 and 7 days, recorded objective pain with the Semmes-Weinstein mechanical esthesiometer (SW test) and subjective pain with the Visual Analog Scale (VAS). Results: 85.6% and 81.5% of patients, respectively, recorded no signs of state anxiety or depression. The correlation between anxiety and depressio…

AdultMalemedicine.medical_specialtyVisual analogue scalemedicine.medical_treatmentPostoperative painOdontologíaAnxietyYoung AdultmedicineHumansProspective StudiesYoung adultDental implantProspective cohort studyGeneral DentistryDepression (differential diagnoses)AgedAged 80 and overDental ImplantsPain PostoperativeDepressionbusiness.industryResearchBeck Depression InventoryMiddle AgedMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Health SurveysCiencias de la saludOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASPhysical therapyAnxietyFemaleSurgerymedicine.symptombusinessFollow-Up StudiesMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Oral health in a group of patients with Rett syndrome in the regions of Valencia and Murcia (Spain): A case-control study

2014

Objectives: Rett syndrome (RS) is a rare disease with oral manifestations that have not been described in detail or in a standardized manner in the literature. The present study describes the oral health of the population with RS in two Spanish regions, following the protocol of the World Health Organization for conducting common oral health surveys. Study Design: A prospective, observational case-control study was carried out, involving a group of patients with RS (n1=41) and a mean age of 13.37±3.19 years, and an age- and gender-matched control group without RS (n0=82). The data referred to oral health and habits were recorded by means of a questionnaire and oral examination was used to d…

AdultPediatricsmedicine.medical_specialtyAdolescentPopulationDentistryOral HealthRett syndromeDental CariesOral hygieneDroolingYoung AdultTonguePrevalenceRett SyndromemedicineHumansProspective StudiesChildProspective cohort studyeducationGeneral Dentistryeducation.field_of_studybusiness.industryResearchCase-control studyMedically compromised patients in Dentistrymedicine.diseasestomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologySpainCase-Control StudiesChild PreschoolFemaleSurgeryObservational studymedicine.symptombusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients

2016

Background Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with s…

Adultmedicine.medical_specialtyAntifungal drugMycoseintensive care medicinelaw.invention03 medical and health sciencesImmunocompromised Hostcritically ill patient0302 clinical medicineRandomized controlled triallawInternal medicineAmphotericin BmedicineHumansAntifungal AgentPharmacology (medical)030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineFluconazoleFluconazole [therapeutic use]Randomized Controlled Trials as Topicbusiness.industryfungal infectionMicafungin030208 emergency & critical care medicinePublication biasMycoses [mortalityClinical trialCritical Illness [mortality]; Amphotericin B [therapeutic use]; Antifungal Agents [therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality; prevention & control]; Randomized Controlled Trials as Topic; Adult; HumansAntifungal Agents [therapeutic use]prevention & control]Relative riskMeta-analysisAmphotericin B [therapeutic use]AnidulafunginCritical IllneCritical Illness [mortality]businessmedicine.drugHuman
researchProduct

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

2014

The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) and methotrexate (MTX), together with the advent of biological therapy. Immunomodulators are being used more often and earlier in the course of the disease.1 The introduction of biologic agents, especially inhibitors of the key proinflammatory cytokine, tumor necrosis factor alpha (TNF-α) initiated a new therapeutic era, whose use has grown continuously since their introduction in 1998.2 With such immunomodulation, the potential for opportunistic infection is a key safety concern for patients with IBD. Opp…

Adultmedicine.medical_specialtyEvidence-based practiceAdolescentOpportunistic infectionSettore MED/12 - GASTROENTEROLOGIAMEDLINEAzathioprineHIV InfectionsSettore MED/17 - MALATTIE INFETTIVEInflammatory bowel diseaseInflammatory bowel diseaseImmunocompromised HostYoung AdultRisk FactorsInfluenza HumanmedicineParasitic DiseasesHumansOpportunistic infectionsIntensive care medicineECCO guidelinesIrritable bowel syndromebusiness.industryPapillomavirus InfectionsGastroenterologyAge FactorsGeneral MedicineHerpesviridae InfectionsMiddle Agedmedicine.diseaseHepatitis BInflammatory Bowel DiseasesHepatitis CVaccinationMycosesInfectious disease (medical specialty)ImmunologyHuman medicinebusinessmedicine.drug
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

Nephrotoxicity in the setting of invasive fungal diseases

2008

Amphotericin B, a broad spectrum antifungal agent, is widely used despite significant adverse events including nephrotoxicity. Nephrotoxicity occurs frequently in patients receiving amphotericin B. Different definitions for nephrotoxicity are reviewed in the context of outcome in patients with invasive fungal diseases. In most publications, mortality was higher in patients experiencing nephrotoxicity and mean hospital length of stay was prolonged. As a consequence, the use of less nephrotoxic antifungal agents could improve treatment outcomes.

Antifungalmedicine.medical_specialtyAntifungal Agentsmedicine.drug_classTreatment outcomeLength of hospitalizationContext (language use)DermatologyNephrotoxicityImmunocompromised HostAmphotericin BAmphotericin BmedicineHumansIn patientIntensive care medicineAdverse effectbusiness.industryGeneral MedicineLength of StayTreatment OutcomeInfectious DiseasesMycosesKidney Diseasesbusinessmedicine.drugMycoses
researchProduct

Presence of potentially pathogenic free-living amoebae strains from well water samples in Guinea-Bissau

2014

Free-living amoebae (FLA) include opportunistic pathogens such as Naegleria fowleri, Balamuthia mandrillaris, and the genera Sappinia and Acanthamoeba. In this study, a survey was conducted in order to evaluate the presence of potentially pathogenic amoebic strains in water samples collected from wells located in the western part of Guinea-Bissau. The samples were left to precipitate for 48 hours and then the sediments were seeded on non-nutrient agar plates containing Escherichia coli spread and cultures were checked daily for the presence of FLA. Identification of FLA strains was based on the morphological and polymerase chain reaction (PCR) using the 18S rDNA or 16S mitochondrial rDNA ge…

Antigens ProtozoanBalamuthiaMicrobiologyNaegleriaBalamuthia mandrillarisBalamuthia mandrillarisMicrobiologyAgar plateImmunocompromised HostWater Supplyparasitic diseasesGenotypeAnimalsHumansGuinea-BissauNaegleria fowleriNaegleria fowleribiologyDrinking WaterPublic Health Environmental and Occupational HealthGenes rRNAAmebiasisGeneral Medicinebiology.organism_classificationAcanthamoebaInfectious DiseasesGene Expression RegulationOriginal ArticleParasitologyPublic HealthSappiniaPathogens and Global Health
researchProduct